Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
|Webcasts|March 4, 2021
Solid Form Screening and Rational Cocrystal Design
Author(s)Lonza
***Live: Thursday, March 4 , 2021 at 11am EST| 8am PST| 4pm GMT| 5pm CET & Asia Pacific: Thursday, March 11, 2021 at 4pm JST | 3pm CST | 6pm AEST | 12:30pm IST*** Solid-form screening and characterization is a crucial part of drug substance development and pre-formulation. Review the underlying fundamentals of various screening methods and case studies on in-silico screening methods.*** On demand available after final airing until March 11, 2022.***
Register free:
Event Overview:
Solid-form screening and characterization is a crucial part of drug substance development and pre-formulation. Knowledge of the underlying fundamentals of polymorphism, hydrates/solvates, salts, and cocrystals is essential to establish an understanding of a drug substance and its solid-form throughout the drug development lifecycle.
In this webcast, experts will discuss many aspects of solid-form screening including in-silico screening, which can save time and speed up the solid-form development process. A case study will review in-silico screening of cocrystals of a pharmacophore using hydrogen bond energies and hydrogen bond propensities. A second case study will examine cocrystallization of nutraceuticals and their versatile use as coformers.
Key Learning Objectives:
1. Understand the importance of solid-form screening and the impact of form selection in pharmaceutical development.
2. Learn how solid-form services can accelerate drug development.
3. Understand the importance of different in-silico screening methods in solid-form development.
Speakers:
Michael Grass, Head, Solid Form Services, Lonza
Abhijeet Sinha, Senior Scientist, Lonza
Time and Date:
Thursday, March 4 , 2021 at 11am EST| 8am PST| 4pm GMT| 5pm CET
Asia Pacific: Thursday, March 11, 2021 at 4pm JST | 3pm CST | 6pm AEST | 12:30pm IST
On demand available after final airing until March 11, 2022
Sponsor: Lonza
Register free:
Related to this article
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.